Story thread · 2 reports / 2 sources
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
247wallst.com · 3h · first report
How the coverage leans
Across 2 sources · syndicated copies counted once
Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly what kind of bet the market is actually making.
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.